Clinical Study of Therapy by Trastuzumab for Breast Cancer

Objective To study the effect of trastuzumab and the prognostic factors in HER-2 + breast cancer by analysis of the clinical data.Methods Based on immunohistochemical results of estrogen(ER),whether using trastuzumab or not,107 patients with HER 2 + breast cancer patients were divided into treated and untreated group,which were divided into ER-and ER + subgroups.Their clinical characteristics were retrospectively reviewed by SPSS17.0 software.The survival rate and prognosis were also analyzed by Kaplan-Meier method and Cox regression.Results Among the 107 HER-2 + breast cancer patients,43 cases were treated by trastuzumab,64 cases were not treated,which had lower survival(P = 0.04).The patients were further divided into ER + treated group(22 cases,20.56%),ER-treated group(21 cases,19.63%),ER + non-treated group(46 cases,42.99%) and ER-non-treated group(18 cases,16.82%).The survival of the 4 groups were significantly different(P = 0.02).The disease-free survival rate of ER-treated group was higher than that of untreated ER-(P = 0.04),and that of ER + treated and untreated groups was in no significant difference(P = 0.25).According to the result of the Cox multiple-factor analysis,the lymph node status and hormone receptor status were important factors for the prognosis of HER-2 + breast cancer patients.The patients with more lymph node metastasis or ER-had poorer prognosis(P 0.05).Conclusion The disease-free survival rate of HER-2 + breast cancer patients is improved by adjuvant trastuzumab therapy,especially of ER-patients.In the HER-2 + breast cancer,the lymph node and hormone receptor status are the important prognostic factors.The patients with lymph node metastasis or ER negative have the worst prognosis.